An extension study after completion of RACE study of Riociguat add on therapy assessing the management of Catheter-Based Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension who remained symptomatic with PVR>4 WU
Latest Information Update: 27 Jun 2021
Price :
$35 *
At a glance
- Drugs Riociguat (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- 27 Jun 2021 New trial record
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society